<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592810</url>
  </required_header>
  <id_info>
    <org_study_id>NL60632.078.17</org_study_id>
    <nct_id>NCT03592810</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess Optimal ECPR Settings After Resuscitation</brief_title>
  <acronym>MOFE</acronym>
  <official_title>Multi-center Observational Study to Assess Optimal ECMO Settings During the First Hours of Extracorporeal Cardiopulmonary Resuscitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Veno-arterial extracorporeal membrane oxygenation (vaECMO) during cardiopulmonary&#xD;
      resuscitation (ECPR) might improve outcome after cardiac arrest. However, it is well&#xD;
      established that reperfusion injury of the brain can cause microvascular and endothelial&#xD;
      dysfunction, leading to cellular necrosis and apoptosis. While performing ECPR, following the&#xD;
      European resuscitation guidelines, it is yet unknown how to set the ECMO settings in order to&#xD;
      minimize ischemia-reperfusion injury of the brain.&#xD;
&#xD;
      Objective: In this study, we want to elaborate on the optimal ECMO settings in the first&#xD;
      three hours after initiation of ECPR.&#xD;
&#xD;
      Study design: Prospective, multi-centre, observational study Study population: All patients&#xD;
      receiving ECPR in the age between 18 and 70 years, with low flow duration&lt;60min and receiving&#xD;
      cerebral oximetry monitoring Intervention: application of an adhesive regional oximetry&#xD;
      sensor on the patient's forehead and withdrawal of 12 ml extra blood in all patients.&#xD;
&#xD;
      Main study parameters/endpoints: Cerebral Performance Category at 6 months. Neuron-specific&#xD;
      enolase (NSE) will be determined from routine blood drawings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CPC score 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>To prospectively identify parameters correlated with Cerebral Performance Category (CPC)* ≤ 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CPC score discharge</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters correlated with a CPC* ≤ 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow coma scale (GCS) day 28</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters correlated with a GCS&gt;13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GCS total</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters correlated with a GCS &gt; 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters correlated to 28 days mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital survival</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters correlated to hospital survival</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Extracorporeal Cardiopulmonary Resuscitation</condition>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>ECPR</arm_group_label>
    <description>All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Settings of the extracorporeal membrane oxygenation (ECMO)</intervention_name>
    <description>Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score</description>
    <arm_group_label>ECPR</arm_group_label>
    <other_name>Measurements of cerebral saturation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients receiving ECPR will be included. The decision to perform an ECPR is made&#xD;
        by the local protocol and clinical judgment of the attending physician.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Witnessed cardiac arrest or signs of life during CPR (such as gasping or movement)&#xD;
&#xD;
          -  Age&gt;18 and &lt; 70 years&#xD;
&#xD;
          -  Duration of low-flow &lt; 60 min before decision to proceed with ECPR&#xD;
&#xD;
          -  High quality CPR (defined as end-tidal carbon dioxide (CO2et) &gt;10 mmHg) provided for a&#xD;
             minimum of 15 minutes without return of spontaneous circulation (ROSC)&#xD;
&#xD;
          -  Presumed cardiac cause of cardiac arrest (such as Chest pain before collapse,&#xD;
             ventricular tachycardia/ventricular fibrillation (VT/VF) as initial rhythm or&#xD;
             ST-elevation on ECG)&#xD;
&#xD;
          -  Cerebral oxymetry monitoring initiated during CPR preceding ECPR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a GCS&lt;15 before CPR.&#xD;
&#xD;
          -  Known pre-arrest cerebral performance category CPC ≥ 3&#xD;
&#xD;
          -  Presumed noncardiac cause&#xD;
&#xD;
          -  Unwitnessed collapse&#xD;
&#xD;
          -  Suspected or confirmed pregnancy&#xD;
&#xD;
          -  ROSC within 5 minutes of Advanced cardiopulmonary life support (ACLS) performed by&#xD;
             emergency medical service (EMS) team&#xD;
&#xD;
          -  Conscious patient&#xD;
&#xD;
          -  Known bleeding diathesis or suspected or confirmed acute or recent intracranial&#xD;
             bleeding&#xD;
&#xD;
          -  Suspected or confirmed acute stroke&#xD;
&#xD;
          -  Known severe chronic organ dysfunction or other limitations to therapy&#xD;
&#xD;
          -  &quot;Do not resuscitate&quot; order or other circumstances that make 180 day survival unlikely&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dinis dos Reis Miranda, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Loes Mandigers, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

